Experimental Therapeutics with a New 10-Deazaaminopterin in Human Mesothelioma: Further Improving Efficacy through Structural Design, Pharmacologic Modulation at the Level of MRP ATPases, and Combined Therapy with Platinums

Nushmia Z. Khokhar, Yuhong She, Valerie W. Rusch, and F. M. Sirotnak

Program in Molecular Pharmacology and Experimental Therapeutics [N. Z. K., Y. S., F. M. S.] and Department of Surgery [V. W. R.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

ABSTRACT

Studies described here sought to evaluate the therapeutic potential of a new 10-deazaaminopterin analogue, 10-propargyl-10-deazaaminopterin (PDX), alone and in combination with platinum compounds in the treatment of human pleural mesothelioma. In vitro studies documented 25–30-fold and 3-fold, respectively, greater cytotoxic potency of PDX compared with methotrexate and another 10-deazaaminopterin, edatrexate, against VAMT-1 and JMN cell lines derived from human mesothelioma. These tumor cell lines were also inhibited by platinum compounds. Cisplatin (CDDP) was somewhat more inhibitory than oxaloplatin and >1 log order in magnitude more inhibitory than carboplatin (CBCDA). Against the JMN tumor xenografted in nude mice, whereas methotrexate and, more so, edatrexate, were potentely growth inhibitory, only PDX brought about substantial regression. By comparison, CDDP and CBCDA, but not oxaloplatin were markedly growth inhibitory to this same tumor in vivo. This high level of therapeutic activity of PDX could be additionally enhanced by coadministration of probenecid, an inhibitor of canicular multispecific organic anion transporter/multidrug resistance-related protein (MRP)-like ATPases, which increased the number of complete regressions by >3-fold. Canicular multispecific organic anion transporter/MRP genes, primarily 1, 3, 4, 5, and 7, were in fact expressed in these human mesothelioma cell lines as determined by real-time reverse transcription-PCR. These same MRP genes, including, to a lesser extent, MRP-4, were also expressed in pleural mesotheliomas derived from patients as shown by the same methodology. When combined with CDDP or CBCDA, PDX achieved 2-fold greater overall regression of the JMN tumor with a 3–4-fold increase in complete regressions, although some attenuation of dosages of each were required in the combination. These results strongly suggest that PDX has significant potential in the treatment of human pleural mesothelioma, particularly when coadministered with probenecid or combined with platinum compounds.

INTRODUCTION

Malignant pleural mesothelioma is a human neoplasm against which current therapeutic approaches have yielded little success (1, 2). Among cytotoxic agents evaluated (1, 2), modest activity has been observed with anthracyclines, platinums, alkylating agents, and folate antagonists. However, duration of response has been short, and there was only a minimal impact on survival. Combination therapy with these agents has also been disappointing (1, 2). More recently, a 10-deazaaminopterin analogue, EDX,3 has shown (3) promising activity against this neoplasm in the context of a group cooperative study.

The 10-deazaaminopterins were designed (4) as 4-amino folate analogues with more efficiency than MTX (1) for reduced folate carrier-mediated internalization and folypolyglutamate synthetase-mediated polyglutamylation in tumor cells. Both of these cellular properties are important determinants (5) of cytotoxicity and therapeutic response to the general class of classical folate antagonists. On the basis of its greater therapeutic activity compared with other 10-deazaaminopterins (6) against human tumor xenografts, EDX was selected for clinical development. This analogue was subsequently found (7) to have promising activity against human NSCLC and breast cancer and one form of soft tissue sarcoma in addition to mesothelioma as mentioned above (3).

After additional studies in experimental models of human cancer, a new analogue within the 10-deazaaminopterin series

Received 2/1/01; revised 6/22/01; accepted 6/29/01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by National Cancer Institute Grants CA08748 and CA56517.
2 To whom requests for reprints should be addressed, at Laboratory for Molecular Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021. Phone: (212) 639-7953; Fax: (212) 794-4342; E-mail: sirotaf@mskcc.org.

3 The abbreviations used are: EDX, edatrexate; MTX, methotrexate; TAMRA, 6-carboxytetramethylrhodamine; NSCLC, non-small cell lung cancer; PDX, 10-propargyl-10-deazaaminopterin; PBCD; probenecid; MRP, multidrug resistance-related protein; CDDP, cisplatin; CBCDA, carboplatin; OXCDCA, oxaloplatin; nt, nucleotide; MTD, maximum tolerated dose; CT, threshold cycle; MSKCC, Memorial Sloan-Kettering Cancer Center.
(PDX) was identified (8), which exhibited therapeutic activity superior to EDX. PDX was found (8) in companion pharmacological studies to be the most efficient permutant for reduced folate carrier-mediated internalization and substrate for folylpolyglutamate synthetase in human tumors among all of the earlier 10-deazaaminopterins examined. All told, the above studies characterized PDX as an excellent candidate for clinical development, which is now underway (9).

We now describe studies of this newest 10-deazaaminopterin analogue, which focus on models of human pleural mesothelioma. Our results document the significantly enhanced cytotoxicity of PDX compared with MTX and EDX against two mesothelioma cell lines of different histological subtypes. They also give evidence of the superiority of PDX compared with MTX and EDX against human mesothelioma xenografted in nude mice. We also markedly enhanced the therapeutic activity of PDX by coadministration of PBCD. This represents an extension of our earlier (10) studies in which we demonstrated that PBCD will selectively inhibit ATP-dependent efflux of [3H]MTX, increase cytotoxicity of folate analogues, including PDX, against tumor cells in culture, and enhance the therapeutic activity of these analogues against tumors when coadministered to animals. This uricosric agent is a selective inhibitor (11, 12) of PDX by coadministration of PBCD. This represents an example of PDX: PBCD will selectively inhibit ATP-dependent efflux of [3H]MTX, increase cytotoxicity of folate analogues, including PDX, against tumor cells in culture, and enhance the therapeutic activity of these analogues against tumors when coadministered to animals. This uricosric agent is a selective inhibitor (11, 12) of canicular multispecific organic anion transporter/MRP class ATPases (13–22), which are known to extrude folate analogues from tumor cells and limit their effectiveness. Finally, we also demonstrate substantial improvement in the therapy of human experimental mesothelioma by combining PDX with either one of two platinums analogues, CDDP or CBDA. Although CBDA has a more acceptable toxicity profile, the relative efficacy of these two platinums has been controversial (23, 24). There seems to be equivalence in activity against some human neoplasms but documented superiority of CDDP against others. Moreover, the usefulness of CBDA in mesothelioma has not been established (1, 2). The results of our studies are presented below.

**MATERIALS AND METHODS**

**Cell Culture Studies.** The mesothelioma cell lines were cultured in RPMI 1640 in accordance with published (4, 8) procedures. The VAMT-1 (sarcomatoid) and JMN (mixed epithelioid/sarcomatoid) cell lines were generously provided by Drs. Brenda Gerwin and Curtis Harris at the National Cancer Institute, Bethesda, MD. Procedures used for the cytotoxicity determinations in cell culture were also described previously (4, 8).

**In Vivo Studies.** During in vivo studies the JMN tumor was maintained in athymic NCR-nu mice by s.c. transplantation at the flank. After tumor growth, a cell suspension in RPMI 1640 was prepared from the excised tumor, centrifuged for 5 min at 1000 × g, and the pellet resuspended in RPMI 1640 with 10% FCS for implantation with an 18-g needle. Later (3–4 days) when tumor diameters averaged 4–5 mm, the mice were randomized among control and treated groups. The MTDs of individual agents or combinations to weight loss and lethality of treated mice. The average tumor diameter (two perpendicular axes of the tumor) was measured in control (diluent treated only) and treated groups by caliper at intervals during treatment and after treatment for 2–10 days or until the nadir in regression was attained. The data are expressed as the increase or decrease in tumor volume in mm3 (mm 3).

Statistical analysis was carried out by the χ2 method (25). Working solutions of MTX, EDX, PDX, CDDP, CBDA, and PBCD were prepared in 0.9% NaCl (pH 7.0). These studies were performed in accordance with the “Principles of Laboratory Animal Care” (NIH publication No. 85–23 revised 1985). NCR-nu mice were purchased from Harlan Sprague Dawley Inc. (Indianapolis, IN).

**Quantitative Reverse Transcription-PCR Analysis.**

Total RNA was prepared with Trizol reagent (Life Technologies, Inc.) from all of the tumor cell lines. First strand cDNA was prepared using the Superscript System (Life Technologies, Inc.). Mesothelioma tumor samples were harvested from patients at the time of surgical resection and snap frozen in liquid nitrogen. mRNA was purified from these tissue samples using the Quick Prep mRNA Purification kit (Amersham Pharmacia) and then reverse transcribed using M-MLV reverse transcriptase and random hexamers (Life Technologies, Inc.). The quantitation of MRP gene expression was carried out with the aid of an ABI Prism 7700 Sequence Detection System (Taqmam; PE Biosystems, Foster City, CA). A detailed description of this methodology has been provided previously (26). Specific cDNAs of interest (MRPs 1–7) and reference cDNA (β-actin) were amplified separately with the Taqman using an oligonucleotide probe with a 5′ fluorescent reporter dye (6FAM) and a 3′ quencher dye (TAMRA; Ref. 26). The original descriptions of the MRP genes have been presented in various publications (13–18, 20, 22, 27–29). The primer and probe sets were designed using Primer Express Software (Applied Biosystems). The sequences are as follows: MRP-1, forward primer starting at nt 1620, 5′-TCATGGTGCCCGTCAATG-3′, reverse primer starting at nt 1698, 5′-CGATTTGCTTTTGCTTTCATGTG-3′, probe starting at nt 1671 6FAM-CATGAAAGCGACTCCAG- CCGTTGAGTGGAATCAGCAA-3′; MRP-2, forward primer starting at nt 4049, 5′-GCTGGAAAGTCATCCCTCACA-3′, reverse primer starting at nt 4148, 5′-GGAGCCTTGTGGAACGCGAT-3′, probe starting nt 4122, 6FAM-CCATTCAATGATAATCTGAC-AACCGGCA-TAMRA; MRP-3, forward primer starting at nt 1380, 5′-TCTACTCATGCATCTTCCT-3′, reverse primer starting at nt 1470, 5′-CCGTTGATGGAAATCAGCA-3′, probe starting at nt 1447, 6FAM-CATGAAACGCACTCCAG-CCAGAACG-TAMRA; MRP-4, forward primer starting at nt 614, 5′-CGATGACCCATGTCCGCA-TAMRA; MRP-4, reverse primer starting at nt 700, 5′-GACTATCGCTGCTGCTGCTT-3′, probe starting at nt 668, 6FAM-CATGGAACGACTGTTAACA-GAGCAGAATGTCCTT-TAMRA; MRP-5, forward primer starting at nt 767, 5′-CTCGAATTATCATGTTTGAATG-3′, reverse primer starting at nt 860, 5′-TCGTTAATTCAAT-

Downloaded from clinicalcancerres.aacrjournals.org on April 20, 2017. © 2001 American Association for Cancer Research.
Fig. 1 Standard curve of C_T value against log of starting quantity of β-actin. ●, standard samples plotted in triplicate. Slope is −3.39; y intercept is 40.55 and correlation coefficient is 0.999.

GCAAAGT-3', probe starting at nt 828, 6FAM-AACAGCCAGCAGTTTCCCGTA-TAMRA; MRP-6, forward primer starting at nt 245, 5'-GCTTTGGATCCGCCCCCATAG-3', reverse primer starting at nt 321, 5'-CAGGGCTTCCCTGTTG-3', probe starting at nt 299, 6FAM-CCAAAGACGGGTTCCCTGAGCGC-TAMRA; and β-actin, forward primer starting at nt 1031, 5'-CGGCCACCCAGCACAATG-3', reverse primer starting at nt 1099, 5'-GCCGGATCCACCGGAGTACT-3', probe starting at nt 1053, 6FAM-TCAAGATCATTGCTTTCCCTGAGCGC-TAMRA. Relative quantitation was done using the comparative C_T method. The C_T indicates the fractional cycle number at which the amplified target reaches a fixed threshold. The amount of target gene (MRPs 1–7) normalized to an endogenous reference (β-actin) is given by 2^(-ΔΔC_T) (30, 31) where ΔC_T is C_T (target gene) – C_T (reference gene). However, this relation is based on the assumption that efficiency of the target and reference amplification be approximately equal. A validation experiment was done comparing serial dilutions of target genes and β-actin. The absolute value of the slope of log input amount versus ΔC_T should be <0.1, indicating that efficiencies of target and reference amplification are approximately equal (32). In our case it varied between 0.021 and 0.051. For comparison we also calculated efficiencies of different runs. Serial dilutions of a control cDNA were run in triplicate amplifying β-actin to generate a standard curve (Fig. 1). The slope of this curve is used for calculating the run efficiency. The relation is given by E = 10^(-1/s) = 1, where E is the efficiency, and S is the slope. In our hands the efficiencies varied from 0.966 to 0.986 with correlation coefficient ≥0.998.

Tissues and Clinical Database. Surgical specimens were obtained from consecutive patients undergoing thoracotomy and surgical resection. They were divided into small samples (3 × 3 × 3 mm), snap frozen, and stored at −140°C. Histological sections were reviewed by a pathologist to identify those tumor samples that had predominantly tumor cells among nucleated cells on the slide. Relevant clinical data were collected for all of the patients and linked to the specimen and the link-up to patient identifiers destroyed by the Tumor Bank before distribution to this project to protect patient confidentiality. Tissue collection and these experiments were performed in accordance with the guidelines of MSKCC.

Materials. Samples of MTX and EDX were obtained from the Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, and Novartis, East Hanover, NJ, respectively. PDX was synthesized at MSKCC. PBCD was obtained from Sigma Chemical Co. (St. Louis, MO) and recrystallized at MSKCC. All of these agents were found to be >98% pure by high-performance liquid chromatography (33). CDDP and CB-CDA were obtained from the pharmacy at MSKCC. NCR-nu mice were purchased from Harlan Sprague Dawley.

RESULTS AND DISCUSSION

Cell Culture Studies. In vitro experiments were carried out with PDX in comparison with MTX and EDX to assess their relative cytotoxicity against two human mesothelioma cell lines. The results of experiments using a 3-h pulse exposure to these folate analogues are given in Table 1. Against both the VAMT-1 and JMN cell lines PDX was found to be 25–30-fold and 3-fold, respectively, more potent than MTX or EDX with values for IC50 varying from low nM (PDX) to high nM (MTX) in concentration. It had already been established in our earlier (10) studies that PBCD will enhance the cytotoxicity of PDX in cell culture against a variety of tumor cell types. Because there is no reason to expect that similar effects of PBCD on PDX cytotoxicity would be any different for mesothelioma cells, we proceeded to expect that similar effects of PBCD on PDX cytotoxicity in vivo would be any different for mesothelioma cells, we proceeded to expect that similar effects of PBCD on PDX cytotoxicity in vivo would be any different for mesothelioma cells, we proceeded to expect that similar effects of PBCD on PDX cytotoxicity in vivo would be any different for mesothelioma cells, we proceeded to expect that similar effects of PBCD on PDX cytotoxicity in vivo would be any different for mesothelioma cells.

In preparation for combination studies to be performed in vivo, studies combining PBCD with PDX.

Table 1 Relative growth inhibition by three folate analogues against human mesothelioma cells

<table>
<thead>
<tr>
<th>Tumor</th>
<th>MTX IC50 (nM)</th>
<th>EDX IC50 (nM)</th>
<th>PDX IC50 (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAMT-1</td>
<td>634 ± 86</td>
<td>77 ± 11</td>
<td>23 ± 4</td>
</tr>
<tr>
<td>JMN</td>
<td>683 ± 65</td>
<td>98 ± 12</td>
<td>27 ± 4</td>
</tr>
</tbody>
</table>

The cells were exposed to various concentrations of each analogue for 3 h then washed and resuspended in drug-free medium. Average of three determinations ± SE of the mean.

Table 2 Relative growth inhibition of three platinum compounds against human mesothelioma cell lines

<table>
<thead>
<tr>
<th>Tumor</th>
<th>CDDP IC50 (μM)</th>
<th>CB-CDA IC50 (μM)</th>
<th>OX-CDA IC50 (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAMT-1</td>
<td>6.5 ± 1</td>
<td>116 ± 22</td>
<td>10.3 ± 2</td>
</tr>
<tr>
<td>JMN</td>
<td>7.0 ± 1</td>
<td>189 ± 26</td>
<td>10.8 ± 2</td>
</tr>
</tbody>
</table>

The cells were exposed to various concentrations of each agent for 3 h and then the agent was removed by washing the cells followed by resuspension in drug-free medium. Average of three experiments ± SE of the means.

Genebank accession numbers for the genes are as follows: MRP-1, NM_004996; MRP-2, NM_000392; MRP-3, NM_003786; MRP-4, NM_005845; MRP-5, NM_005688; MRP-6, NM_001171; MRP-7, AL133613; and β-actin, XM_004814.
Table 3  Treatment of the JMN human mesothelioma with classical folate analogues with and without probenylicd

<table>
<thead>
<tr>
<th>Agent</th>
<th>Dose (mg/kg)</th>
<th>Weight change (%)</th>
<th>Average tumor diameter (mm ± SE)</th>
<th>Change in tumor volume (mm³)</th>
<th>Average regression (%)</th>
<th>Complete regressions (no./total)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX</td>
<td>40</td>
<td>0.3</td>
<td>8.3 ± 1</td>
<td>+1771</td>
<td>0/12</td>
<td></td>
</tr>
<tr>
<td>EDX</td>
<td>40</td>
<td>0.1</td>
<td>5.6 ± 1</td>
<td>+205</td>
<td>0/12</td>
<td></td>
</tr>
<tr>
<td>PDX</td>
<td>60</td>
<td>0.1</td>
<td>4.8 ± 1</td>
<td>+92</td>
<td>0/9</td>
<td></td>
</tr>
<tr>
<td>PDX + PBCD</td>
<td>60 + 125</td>
<td>0.1</td>
<td>3.0 ± 1</td>
<td>-25</td>
<td>52</td>
<td>2/12</td>
</tr>
</tbody>
</table>

a See text for experimetal details. Three to four experiments using three to four mice/group.
b Two of nine mice exhibited no regrowth of tumor 3 weeks after cessation of treatment.

vivo (see below), we also compared the cytotoxicity of three platinum compounds in the same manner against these same human mesothelioma cell lines. The data in Table 2 show that CDDP was somewhat more cytotoxic than the organoplatinum OXCDCA against these cell lines. By comparison, the cytotoxic potency of the organoplatinum CBCDA was substantially less than the other two platinum compounds. Values for IC50 obtained against these cell lines. By comparison, the cytotoxic potency of the organoplatinum CDDP was somewhat more cytotoxic than the organoplatinum human mesothelioma cell lines. The data in Table 2 show that these platinum compounds in the same manner against these same mice to these agents differed by tolerances than the other two platinum compounds. Values for IC50 obtained with CBCDA were 10-15- and OXCDA against these cell lines. By comparison, the cytotoxic CDDP was somewhat more cytotoxic than the organoplatinum more of these compounds. Values for IC50 obtained with CBCDA were 10-15- and 18-25-fold higher against both VAMT-1 and JMN.

Animal Studies. Because of the minimal growth potential as xenografts in nude mice of most human mesotheliomas available to us, we were only able to conduct efficacy studies in vivo with the JMN tumor. However, the results obtained with the folate analogues and platinum compounds with this tumor were for the most part impressive and consistent with results obtained (8, 10) with these agents against other human tumors. The results of experiments comparing the efficacy of MTX, EDX, and PDX on a schedule of q3–4 against the JMN tumor are given in Table 3. The data show that tolerances (MTD) of these mice to these agents differed by ≤50% with greatest tolerance seen in the case of PDX. The MTD for each antifolate was determined in extensive (6, 8) preliminary experiments relating dosage to weight loss and lethality of NCR-nu mice treated on the same schedule of administration. In these experiments, MTX was found to be highly inhibitory to tumor growth, suppressing growth to ~90%. EDX was found to be more inhibitory (P < 0.05) than MTX suppressing growth by 95%. In sharp contrast to these results, which documented no regression of tumor, PDX brought about 50% regression of the JMN tumor with some animals showing no palpable tumors shortly after cessation of treatment.

Also, shown in this table (Table 3) are the results of experiments in which PBCD was coadministered with PDX against the JMN tumor. In our other studies, this organic anion had been shown (10–12) to inhibit the extrusion of PDX and MTX from tumors ostensibly by an MRP-like ATPase, thus, increasing their net accumulation within tumor cells. In the case of other human tumors, the probable effect of PBCD on this ATPase(s) was shown (10, 16, 17, 19) to markedly retard extrusion of PDX from the tumor and increase its efficacy. In the new experiments, PDX also exhibited (data not shown) the same MTD (60 mg/kg) alone and when coadministered with 125 mg/kg PBCD on the same schedule of administration as in the earlier studies. The data given in Table 3 show that there was marked enhancement in the efficacy of PDX against the JMN tumor. This was seen as an increase in the degree of regression (P < 0.01) and in the number of mice (P < 0.01) showing no tumor after cessation of treatment. Moreover, some animals treated with PDX and PBCD did not have tumor regrowth after complete regression.

In view of the above results, it was of interest to examine these mesothelioma cell lines for the expression of MRP family genes. The expression of these genes in these tumors would be consistent with the notion that the enhanced therapeutic effect of PBCD with PDX was mediated through inhibition of one or more of these ATPases. Biochemical evidence of such an effect in other human tumor cells was actually provided (10–12, 19, 20) earlier by showing that PBCD was a strong inhibitor of ATP-dependent efflux of [3H]MTX. Our earlier studies (10) with human NSCLC, prostate, and mammary tumors have also documented consistent expression of MRP-1, -4 and -7 genes in these tumors. We used real-time PCR (Fig. 1) to determine the relative expression levels of MRP genes in human mesothelioma. We found (Fig. 2; Table 4) consistently prominent expres-
expression of MRP-1, -3, -4, -5 genes in the JMN and VAMT-1 human mesothelioma cell lines. We also found (Table 4) similar levels of expression of MRP-1, -3, -5, and -7 but less so for MRP-4 in several mesotheliomas derived directly from patients. Although there was considerable variability in the level of expression of these genes among these tumors, the overall pattern of expression was the same in both epithelioid and mixed tumor (epithelioid/sarcomatoid) samples. Interestingly, the relative expression of these genes was highest in one sample of a sarcomatoid tumor that also showed higher levels of expression of MRP-2.

Table 4  Relative expression of MRP genes in human mesothelioma*

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>JMN</td>
<td>4.8</td>
<td>0.11</td>
<td>2.4</td>
<td>2.4</td>
<td>1.8</td>
<td>0.008</td>
<td>1.3</td>
</tr>
<tr>
<td>VAMT1</td>
<td>9.5</td>
<td>0.074</td>
<td>0.9</td>
<td>6.0</td>
<td>0.9</td>
<td>0.05</td>
<td>0.85</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient samples</th>
<th>1 mixed</th>
<th>2 mixed</th>
<th>3 (epith)</th>
<th>4 (epith)</th>
<th>5 mixed</th>
<th>6 (sarco)</th>
<th>7 (epith)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4.7</td>
<td>12.8</td>
<td>3.8</td>
<td>13</td>
<td>5.3</td>
<td>14.2</td>
<td>4.9</td>
</tr>
<tr>
<td></td>
<td>0.27</td>
<td>0.24</td>
<td>0.04</td>
<td>0.23</td>
<td>0.1</td>
<td>1.0</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>2.43</td>
<td>6.7</td>
<td>1.7</td>
<td>0.87</td>
<td>2.4</td>
<td>18.5</td>
<td>1.26</td>
</tr>
<tr>
<td></td>
<td>1.0</td>
<td>1.15</td>
<td>0.35</td>
<td>0.4</td>
<td>0.35</td>
<td>0.72</td>
<td>0.97</td>
</tr>
<tr>
<td></td>
<td>2.3</td>
<td>0.034</td>
<td>1.1</td>
<td>3.25</td>
<td>2.2</td>
<td>9.65</td>
<td>1.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3.6</td>
<td>0.05</td>
<td>0.094</td>
<td>0.12</td>
<td>1.75</td>
<td>0.09</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2.3</td>
<td>4.15</td>
<td>4.48</td>
<td></td>
<td>7.7</td>
</tr>
</tbody>
</table>

* All values are averages of two determinations done in duplicate differing < ± 15% using human β actin as the internal reference gene. The values shown are normalized to the reference gene × 1000.

Table 5  Treatment of the JMN human mesothelioma with various platinum compounds*

<table>
<thead>
<tr>
<th>Agent</th>
<th>Dose (mg/kg)</th>
<th>Weight change (%)</th>
<th>Average tumor diameter (mm ± SE)*</th>
<th>Change in tumor vol (mm³)</th>
<th>No. of animals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDDP</td>
<td>2</td>
<td>−4</td>
<td>4.2 ± 1</td>
<td>−53</td>
<td>9</td>
</tr>
<tr>
<td>CBDDCA</td>
<td>50</td>
<td>−3</td>
<td>4.3 ± 1</td>
<td>+53</td>
<td>9</td>
</tr>
<tr>
<td>OXDDCA</td>
<td>7</td>
<td>−5</td>
<td>7.8 ± 2</td>
<td>+950</td>
<td>9</td>
</tr>
</tbody>
</table>

* See text for experimental details. Average of three experiments of the 3 mice/group.

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>Weight change (%)</th>
<th>Average tumor diameter (mm ± SE)*</th>
<th>Change in tumor vol (mm³)</th>
<th>No. of animals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

platinum alone and in combination with PDX were determined (data not shown) in extensive experiments relating dosage to weight loss and lethality of NCR-nu mice. However, despite this dosage attenuation, the combined effect of these agents was greater (Table 6) than either PDX or platinum alone. Compared with PDX both combinations brought about ~2-fold more regression (P < 0.05) of the tumor and a 3–4-fold increase (P < 0.01) in mice showing palpable tumors.

Our results clearly document the superiorit of PDX compared with MTX and EDX against the JMN human mesothelioma xenografted in nude mice. Given the consistency of the results obtained in vivo with the companion in vitro data (Table 1) and the well-documented (8, 9) improvement in activity of PDX compared with MTX and EDX obtained against several other human tumor types, there is a reasonable basis for assuming that PDX could have significant impact on the treatment of this neoplastic disorder in patients. This potential is clearly manifested in the case of PDX combined with platinum analogues, because members within both categories of agents have already been identified (1–3) as active in human mesothelioma.

Of interest as well were our results showing that PBCD markedly enhanced the activity of PDX against the JMN tumor. As in the case of this human mesothelioma, we have shown (10) similar enhancement in the efficacy of PDX by PBCD against drug-naive human NSCLC, prostate, and mammary neoplasms. Because drug-naive human mesothelioma, like these other tumors, expresses several members of the MRP ATPase family of genes, the likely targets of PBCD (16–21), this mechanist-based approach may clearly extend to human pleural mesothe-
lioma. Whereas it is not yet known which MRP-ATPase(s) is primarily responsible for extruding PDX from these tumors, the results obtained with PBCD provide proof-of-principle that these ATPases do impact on intrinsic sensitivity of these tumors by their role in determining net intracellular accumulation of PDX and that these ATPases can at least be partially suppressed by pharmacological means. It should also be mentioned that potential exists for the favorable modulation by PBCD of intrinsic resistance to the platinum compounds in the same context as that discussed above. However, the coadministration of 125mg/kg PBCD with either CDDP or CBDA had no beneficial effect compared with these platinums alone (data not shown) on the JMN tumor in mice. We attribute this negative result to the fact that MRP-2, which is associated with resistance to CDDP (13) and its encoded ATPase, is inhibited (19) by PBCD and is not expressed in this tumor. In contrast, ≥3 MRP genes appear to be relevant to the cytotoxic action of PDX. Clearly, additional work will be required addressing this issue of PBCD-mediated pharmacological modulation of intrinsic resistance to other agents, which may be permeants for MRP-2 or other MRP-encoded ATPases.

REFERENCES


Downloaded from clincancerres.aacrjournals.org on April 20, 2017. © 2001 American Association for Cancer Research.
Experimental Therapeutics with a New 10-Deazaaminopterin in Human Mesothelioma: Further Improving Efficacy through Structural Design, Pharmacologic Modulation at the Level of MRP ATPases, and Combined Therapy with Platinums

Nushmia Z. Khokhar, Yuhong She, Valerie W. Rusch, et al.